Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California. Show more
Location: 10275 Science Center Dr., Suite 1710, San Diego, CA, 92121, United States | Website: https://zentalis.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
83.46M
52 Wk Range
$1.01 - $5.44
Previous Close
$1.16
Open
$1.14
Volume
1,157,666
Day Range
$1.13 - $1.27
Enterprise Value
-206.8M
Cash
332.5M
Avg Qtr Burn
-37.88M
Insider Ownership
13.58%
Institutional Own.
80.34%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Azenosertib (ZN-c3) (oral inhibitor of WEE1) +/- niraparib Details Ovarian cancer, Cancer, PARPi Resistant Ovarian Cancer | Phase 2 Data readout | |
Azenosertib (ZN-c3) (oral inhibitor of WEE1) mono Details Cyclin E1+ platinum-resistant ovarian cancer (PROC) | Phase 2 Data readout | |
Azenosertib (ZN-c3) (oral inhibitor of WEE1) Details Uterine disease, Cancer | Phase 2 Data readout | |
Azenosertib (ZN-c3) (oral inhibitor of WEE1) Details Cancer, Solid tumor/s | Phase 1b Data readout | |
Azenosertib (ZN-c3) (oral inhibitor of WEE1) w/ multiple chemo Details Ovarian cancer, Cancer, Platinum-resistant ovarian cancer | Phase 1b Update | |
Azenosertib (ZN-c3) + gemcitabine Details Cancer, Osteosarcoma | Phase 1 Update | |
Azenosertib (ZN-c3) (oral inhibitor of WEE1) Details Ovarian cancer, Cancer, Platinum Sensitive Ovarian Cancer | Phase 1 Update | |
ZN-d5 (oral selective inhibitor of B-cell lymphoma 2 (BCL-2)) + azenosertib Details Acute myeloid leukemia, Cancer | Failed Discontinued | |
ZN-c5: Oral SERD (Monotherapy) Details Breast cancer, Cancer | Failed Discontinued | |
ZN-d5 (oral selective inhibitor of B-cell lymphoma 2 (BCL-2)) Details Cancer, relapsed or refractory light chain amyloidosis | Failed Discontinued | |
ZN-c5 (Oral SERD) +Verzenio® (abemaciclib) Details Breast cancer, Cancer | Failed Discontinued | |
Azenosertib (ZN-c3) + encorafenib and cetuximab Details Cancer, Metastatic colorectal cancer | Failed Discontinued |